An outflow conduit for a heart pump, the outflow conduit including an inlet configured to be attached to a pump outlet of the heart pump to receive blood therefrom, an outlet configured to be connected to an arterial vessel, wherein the outlet includes a flared portion to minimise flow restrictions and a sidewall defining an internal cavity extending from the inlet to the outlet, the cavity being configured to transport blood from the heart pump to the arterial vessel.
A61M 60/178 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient implantables dans ou sur le cœur, ou autour du cœur prélevant le sang d’un ventricule et renvoyant le sang vers le système artériel par une canule externe au ventricule, p. ex. dispositifs d’assistance pour ventricule gauche ou droit
A61M 60/226 - Pompes pour le sang à déplacement non positif comportant un élément rotatif agissant sur le sang, p. ex. un impulseur le flux de sang à travers l’élément rotatif ayant des composants principalement radiaux
The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
3.
METHODS OF TREATING UVEAL MELANOMA WITH A PKC INHIBITOR
Provided herein is a combination therapy and methods of using such combination therapy as a neoadjuvant therapy and/or an adjuvant therapy in uveal melanoma, inter alia to reduce the risk of metastasis and/or enucleation, and/or preserving eye function. Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults. The protein kinase C (PKC) inhibitor, sotrastaurin, has been shown to have activity against certain PKC isototypes and has been shown to selectively inhibit the growth of uveal melanoma cells harboring GNAQ mutations by targeting PKC/ERK1/2 and PKC/NF-xB pathways.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample such as serum.
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
The present disclosure relates to a method for treating a haematological malignancy or pre-malignant condition in a subject. In one particular application, the method involves administering to a subject with Acute Myeloid Leukaemia (AML) and preferably an AML overexpressing miR-10a (eg NPMc+ AML), an effective amount of a first agent comprising an MDM2/MDMX inhibitor (eg Nutlin-3a), a second agent comprising an inhibitor of MiR-10a expression and/or activity (eg an antisense oligonucleotide targeted to MiR-10a), and optionally, a chemotherapeutic agent such as a "standard of care" (SOC) chemotherapeutic agent for AML (eg cytarabine).
The present invention provides a method of modulating appetite and/or body weight in a subject, said method comprising administering to said subject an effective amount of a MIC-1-modulating agent, wherein said agent increases or decreases the amount of MIC-1 present in said subject, or inhibits or enhances the biological activity of MIC-1 present in said subject.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
Apparatus for use with a ventricular assist device that is assisting cardiac function of a biological subject, the apparatus including one or more electronic processing devices that determine pressure changes in the ventricle over one or more cardiac cycles using an aortic pressure derived from a measured blood pressure, a pump head pressure derived based on a pump flow rate and outlet fluid conduit pressure losses derived based on a pump flow rate, a fluid conduit diameter and haematocrit amount. The processing device(s) then determine volume changes in the ventricle at least in part using a pump blood flow derived based on a pump flow rate and an ejection volume based on an aortic valve opening duration, and use the pressure and volume changes to at least one of derive a ventricular function indicator indicative of ventricular function and control the ventricular assist device.
A61M 1/12 - Pompes pour le sang; Cœurs artificiels; Dispositifs pour aider mécaniquement la circulation, p.ex. pompes à ballon intra-aortique implantables dans le corps
Methods for controlling body weight and/or appetite in a subject are disclosed. In some embodiments, the methods involve administering to an overweight or obese subject an effective amount of a first agent comprising MIC-1, a MIC-1 agonist and/or a MIC-1-inducing agent, and a second agent comprising leptin and/or a leptin agonist, for the purpose of achieving weight loss. In other embodiments, the methods involve administering to an anorexic or cachectic subject an effective amount of a MIC-1-inhibiting agent and a leptin-inhibiting agent, for the purpose of increasing body weight and/or appetite in a subject.
C07K 16/26 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des hormones
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
The present disclosure is based on methods for detecting and quantifying lentivirus (human immunodeficiency virus, HIV-1 or HIV-2) DNA and RNA in a biological sample.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
11.
Methods for discriminating between HIV-1 and lentiviral vectors
The present disclosure provides compositions (i.e., amplification primers and probes), methods, and kits that are particularly useful for detecting and/or quantifying nucleic acids present in a sample, such as those derived from HIV or a lentiviral vector.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Methods for controlling body weight and/or appetite in a subject are disclosed. In some embodiments, the methods involve administering to an overweight or obese subject an effective amount of a first agent comprising MIC-1, a MIC- 1 agonist and/or a MIC-1-inducing agent, and a second agent comprising leptin and/or a leptin agonist, for the purpose of achieving weight loss. In other embodiments, the methods involve administering to an anorexic or cachectic subject an effective amount of a MIC-1-inhibiting agent and a leptin-inhibiting agent, for the purpose of increasing body weight and/or appetite in a subject.
Device and methods for free-form biofabrication, the device comprising a plurality of extrusion chambers that are hand-holdable and individually actuatable, an extrusion nozzle having a plurality of openings that are closely adjacent one another and respectively fluidly connected to the plurality of extrusion chambers, wherein one of the extrusion chambers contains a bioink that comprises living cells which, in use, are controllably deliverable in situ with a structural biomaterial to form a biofabricated structure.
The present disclosure is based on methods for detecting and quantifying lentivirus (human immunodeficiency virus, HIV-1 or HIV-2) DNA and RNA in a biological sample.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytoking-1 (MID-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p. ex. adaptation de la température, irradiation
16.
GENE THERAPEUTIC FOR THE TREATMENT OF HIV AND USES THEREOF
The present disclosure provides for an expression vector comprising (i) at least one nucleic acid sequence encoding a transcriptional gene silencing element; and (ii) at least two other nucleic acid sequences selected from the group consisting of a nucleic acid sequence that encodes a nucleic acid molecule that inhibits an HIV co-receptor; a nucleic acid sequence that encodes an HIV fusion inhibitor protein; a nucleic acid sequence encoding an inhibitor of HIV replication; and a nucleic acid sequence encoding an inhibitor of viral entry. The combination of the three mechanisms in a single expression vector provides for novel means of inhibiting HIV-1.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
The present disclosure provides compositions (i.e., amplification primers and probes), methods, and kits that are particularly useful for detecting and/or quantifying nucleic acids present in a sample, such as those derived from HIV or a lentiviral vector.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
18.
METHOD AND APPARATUS FOR DETERMINING AORTIC VALVE OPENING
Apparatus for determining opening of an aortic valve of a biological subject, the apparatus including an electronic processing device that determines a pump speed of a ventricular assist device that is assisting cardiac function of the biological subject, analyses the pump speed to determine a pump speed indicator at least partially indicative of changes in pump speed and uses the pump speed indicator to determine an opening indicator indicative of opening of the aortic valve.
A61M 1/12 - Pompes pour le sang; Cœurs artificiels; Dispositifs pour aider mécaniquement la circulation, p.ex. pompes à ballon intra-aortique implantables dans le corps
A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
A61M 1/10 - Pompes pour le sang; Cœurs artificiels; Dispositifs pour aider mécaniquement la circulation, p.ex. pompes à ballon intra-aortique
Described herein are silencing nucleic acids, compositions comprising silencing nucleic acids, and methods of utilizing the silencing nucleic acids to inhibit HIV replication in a cell infected with HIV. In some embodiments, the disclosed methods comprise contacting a cell or population of cells infected with HIV with at least one silencing nucleic acid that targets a specific sequence of the 5' LTR of HIV.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
Apparatus for use with a ventricular assist device that is assisting cardiac function of a biological subject, the apparatus including an electronic processing device that determines a flow rate of blood through the ventricular assist device, analyses the flow rate to determine a flow parameter value at least partially indicative of a change in the flow rate during diastole; and uses the flow parameter value to either derive at least one blood pressure parameter value at least partially indicative of a blood pressure in the biological subject or control the ventricular assist device.
A61M 1/12 - Pompes pour le sang; Cœurs artificiels; Dispositifs pour aider mécaniquement la circulation, p.ex. pompes à ballon intra-aortique implantables dans le corps
Disclosed is a method of cluster analysis of a data set of multidimensional observations. The method comprises: determining a set of quasi-optimal binwidths for the data set; partitioning, for a current binwidth in the set of quasi-optimal binwidths, the data set into a plurality of bins of width equal to the current binwidth; determining the number of modes of the partitioned data set for the current binwidth; and repeating the partitioning and determining the number of modes for each binwidth in the set of quasi-optimal binwidths. The number of clusters in the data set is the largest determined number of modes over the set of quasi-optimal binwidths.
09 - Appareils et instruments scientifiques et électriques
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Computer software for use in health care and hospital database management, spreadsheets and word processing; downloadable computer programs for use in health care and hospital database management, spreadsheets and word processing; downloadable electronic publications, namely, brochures, newsletters, circulars, prescription pads, illustrations, written reports featuring homework assignments, indexes of information resources, instruction sheets, and testimonial documents, all in the field of health care and hospital and health care management Education and training services, namely, conducting classes, seminars, conferences, webinars and workshops in the fields of health, mental health, and well-being Advisory services, relating to medical services, health care and mental healthcare; providing medical services, mental health care services, complementary medical services provided via a global computer network, namely, providing medical information and treatment online
23.
METHODS OF DIAGNOSING AND PROGNOSING COLONIC POLYPS
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (USA)
Inventeur(s)
Breit, Samuel, Norbert
Brown, David, Alexander
Hance, Kenneth, W.
Lanza, Elaine
Rogers, Connie, J.
Abrégé
Methods of diagnosing or prognosing a disease or condition associated with increased or over expression of macrophage inhibitory cytokine-1 (MIC-1) are disclosed. The methods typically involve detecting a change in the amount of MIC-1 in a test body sample from a subject taken at two or more time points. The change in the amount of MIC-1 may be adjusted for the effect of at least the following factors as appropriate: the gender of the subject, the age of the subject, the body mass index (BMI) of the subject, the subject being a smoker, the subject being a user of NSAIDs, and the waist-to-hip ratio where the subject is female. The methods are particularly suitable for diagnosing or prognosing the presence of one or more colorectal polyp(s).
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
25.
Method for detecting antigen specific or mitogen-activated T cells
The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/or CD8+ T cells is also disclosed.
The invention relates to the field of medical prognostics. In particular, the invention relates to methods for predicting prostate cancer progression and overall survival prognosis in a subject involving the detection of elevated amounts of macrophage inhibitory cytokine- 1 (MIC-I) in a test body sample such as serum.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
27.
A METHOD OF TREATING CACHEXIA WITH THE REMOVAL OR INACTIVATION OF MACROPHAGE INHIBITORY CYTOKINE-1
A method of treating cachexia is disclosed involving the removal or inactivation of macrophage inhibitory cytokine-1 (MIC-1) present in the blood, plasma or serum of a cachexia subject. In one embodiment, the method comprises the steps of providing a suitable substrate for binding MIC-1 (eg a substrate provided with a MIC-1-binding molecule), treating blood, plasma or serum removed from a subject by contacting the blood, plasma or serum ex vivo with the substrate such that MIC-1 present in the blood, plasma or serum is bound to the substrate, separating the treated blood, plasma or serum from the substrate, and thereafter returning the treated blood, plasma or serum to the subject. Also disclosed, is a method of diagnosing or prognosing cachexia in a subject, said method comprising determining the amount of MIC-1 present in the subject.
A method of identifying an antigen-specific regulatory T cell (Treg) from a subject is discussed wherein the method comprises quantitatively or qualitatively detecting co-expression of each of cell markers CD4, CD25 and CD134, or alternatively, each of cell markers CD8, CD25 and CD137, as well as one or more cell markers selected from the group of Treg cell markers consisting of CD39, CD73, CD127, CTLA-4 and Foxp3 on a cell in a suitable lymphocyte-containing sample from the subject in response to exposure to a target antigen. Also discussed are methods of isolating and expanding the identified antigen-specific Treg population, which may permit antigen-specific Treg cell therapy.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
29.
AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE (MIC-1) ACTIVITY
The invention relates to a method and novel types of agents for modulating appetite and/or body weight in a subject. Moreover, the invention relates to a method of screening for agents which interact and modulate the activity of the receptor complex for macrophage inhibitory cytokine-1 (MIC-1).
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Method of modulating appetite and/or body weight in a subject by administering to the subject an effective amount of a MIC-1 modulating agent. The agent is selected from (i) MIC-1 inhibiting agents which decrease the amount of endogenous MIC-1 in the subject, (ii) MIC-1 inhibiting agents which inhibit the activity of endogenous MIC-1 in the subject, (iii) MIC-1 enhancing agents which enhance the amount of endogenous MIC-1 in the subject, and (iv) MIC-1 enhancing agents which enhance the activity of endogenous MIC-1 in the subject.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
31.
A METHOD FOR DETECTING ANTIGEN-SPECIFIC OR MITOGEN-ACTIVATED T CELLS
The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/ or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/ or CD8+ T cells is also disclosed.
